PF-Atlas › Clinical Trials › NCT03186365

8 Weeks Versus 12 Weeks of Elbasvir/Grazoprevir in Treatment-naïve CHC With Mild Fibrosis

Zepatier Oral Product · Phase 3

Registry ID
NCT03186365
Phase
Phase 3
Status
Completed
Drug / intervention
Zepatier Oral Product
Sponsor
Kaohsiung Medical University Chung-Ho Memorial Hospital
Start
2017-06-12
Enrollment
82
Locations
1

About this trial

Grazoprevir plus elbasvir 12 to 16 weeks is now approved for chronic hepatitis C (CHC) genotype 1, 4, or 6 infection regardless liver disease severity. The current study aims to explore the efficacy and safety of 8-week grazoprevir/elbasvir in HCV-1b patients with mild liver fibrosis

View NCT03186365 on ClinicalTrials.gov →

Explore related

All Zepatier Oral Product trialsAll IPF trials
Medical disclaimer. This page summarizes public trial data for NCT03186365 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.